• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

New agreement signed to join forces to tackle Chagas disease

Geneva, Switzerland / Barcelona, Spain — 15 Mar 2010
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Today, Drugs for Neglected Diseases initiative, the Barcelona Centre for International Health Research and the Clinic Foundation for Biomedical Research signed an agreement to join forces on clinical research on Chagas disease. Dr.  Bernard Pècoul, Executive Director of the Drugs for Neglected Diseases initiative (DNDi), Dr. Pedro L. Alonso, Director of the Barcelona Centre International Health Research (CRESIB)/Hospital Clínic-Barcelona University, and Mr. Emili Bargalló, Director of the Clinic Foundation for Biomedical Research (FCRB), signed the agreement, which will allow enhancing and maximizing resources and efforts in clinical research for Chagas diseases, with the ultimate goal to improve and obtain effective treatments.
[Español]

Over eight million people across Central and South America are infected with Chagas disease, and every year an estimated 14,000 people die as a consequence of the infection. Chagas kills more people in this region than any other parasite-borne disease, but as a result of migration also surfaces in non-endemic countries and regions as Australia, North America, Japan and Europe.

Currently, there are only two treatments for Chagas disease available: nifurtimox and benznidazole. Discovered decades ago, these drugs have limited efficacy and a poor tolerability profile in adults; this is why, the development of a new, effective treatment is an urgent need in the fight against Chagas disease. DNDi and CRESIB will work on establishing and fostering joint research projects, harmonizing procedures to support the implementation and start off clinical trials while maximizing the impact of the resources and benefits from both sides, sharing their experiences, facilities and contacts with the goal to progress in obtaining an effective treatment for Chagas disease.

Led by Dr. Joaquim Gascon, CRESIB is an institution of reference in the field of research of Chagas disease, which also has created a specialised care centre for adults suffering from Chagas disease in Cochabamba, Bolivia. This initiative fell within the framework of a cooperation project funded jointly by the Spanish and Catalan Cooperation Agencies (AECID-ACCD), the researcher Professor Faustino Torrico at the Universidad Mayor de San Simón in Cochabamba, and the National Chagas Plan (Bolivia), in order to exchange management models, promote research projects and share working groups.

DNDi is a not-for-profit product development partnership, working in research and development (R&D) and is driven by the needs of the patients. DNDi, with this agreement will be able to boost its research projects aiming at developing new, effective treatments for Chagas disease. In addition to sponsoring and designing the project, DNDi recently added, through an agreement signed with the Japanese pharmaceutical company Eisai, the development of a promising drug, E1224, a ravuconazole pro-drug (an antifungal, which is an effective product to fight fungal infections), to treat Chagas disease. DNDi will coordinate the phase IIA/B clinical trials with E-1224, showing in vivo and in vitro activity against the pathogen responsible for Chagas disease. The first phase in the assessment of the compound will be conducted in Bolivia, and the follow-up will have a multi-centric approach involving the participation of the Hospital Clínic in Barcelona, amongst others.  This new agreement with CRESIB and FCRB will increase the possibilities of success, strengthening the scientific capacities initially in Bolivia, and later in the Hospital Clínic in Barcelona. The director of CRESIB, Dr. Pedro L. Alonso, says: “DNDi and CRESIB share a common interest in providing sustainable and affordable treatments for neglected diseases such as Chagas disease. Our collaboration will generate innovative alternatives to develop new treatments and new diagnostic tools.” Dr. Bernard Pécoul, Executive Director of DNDi states: “It has been over 100 year since Chagas disease was discovered, but it still remains one of the most neglected diseases. Very little investment has been put into research and development. This collaboration is a great opportunity to bolster both parties’ efforts to achieve rapidly significant international progress in drug and clinical research”.

About Chagas Disease
Chagas disease is a public health problem, not only in the poorest areas in Latin America, but through migration also increasingly in non-endemic countries. The disease is caused by the parasite Trypanosoma cruzi, which is transmitted primarily by insects known as “kissing bugs” or vinchuca. Chagas disease occurs in two stages. An acute stage, where the affected persons are either asymptomatic or show unspecific symptoms; and a chronic stage in which 30-40% of the cases develop serious heart or the digestive complications. If left untreated the condition may lead to death.

About DNDi (www.dndi.org)
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit product development partnership, working to research and develop new and improved treatments for neglected diseases, in particular human African trypansomiasis, leishmaniasis, Chagas disease, and malaria. DNDi was established in 2003, by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia and the Pasteur Institute from France, Médecins Sans Frontières (MSF) and with the UNDP/World Bank/WHO Special Programme for the Research and Training in Tropical Diseases (TDR), acting as a permanent observer.

DNDi seeks to fill some of the existing gaps in essential drug R&D, implementing and coordinating projects in this field, in collaboration with the international scientific community, the public sector, the pharmaceutical industry and other partners. DNDi, based in Geneva, has a permanent team of 30 scientific researchers, in addition to other professionals.  DNDi has the largest R&D portfolio for kinetoplastid diseases. Since 2007, DNDi has delivered three products, two fixed-dose anti-malarials “ASAQ” (artesunate/amodiaquine) and “ASMQ” (artesunate/mefloquine), and a combination treatment for the advanced stage of sleeping sickness, “NECT” (nifurtimox-eflornithine combination therapy). Furthermore, in 2009 DNDi signed a collaboration and license agreement with the Japanese pharmaceutical company Eisai Co. Ltd. for the clinical development of the promising compound E1224, to treat Chagas disease. The pipeline for Chagas disease also includes a paediatric formulation of benznidazole.


About CRESIB
(www.cresib.cat)
The Barcelona Centre for International Health Research, CRESIB (Hospital Clínic- Barcelona University), is a global health research institute created by leading institutions in the academic and biomedical research field in Barcelona: Hospital Clínic, Barcelona University and IDIBAPS that, together with the Generalitat de Cataluña, seeks to address the new international health challenges of the 21st Century. CRESIB’s mission is to carry out international studies relevant to improve the health of the populations living in or migrating from poor areas. CRESIB’s activity revolves around four focal points: research in the field of diseases related to poverty and migratory flows, training-capacity building (developing its own training programmes  in collaboration with other institutions), technical and health cooperation and assistance (with Central and South America, Maghreb, Sub-Saharan Africa, Asia and Oceania), and research platforms (Mozambique: Centro de Investigaçao em Saúde de Manhiça, CISM-Fundaçao Manhiça, Morocco: Ministry of Health, Mother and Child Programme, and in Bolivia: Universidad Mayor de San Simón, Ministry of Health, National Chagas Programme). Last year, CRESIB formalised, through Fundació Clínic per a la Recerca Biomédica (Clinic Foundation for Biomedical Research), the training and research platform with the Universidad Mayor de San Simón of Cochabamba. The creation of this new centre, following the guidelines of the Bolivian MoH National Chagas Plan, contributes, in a relevant way, to consolidating a public health action and addressing endemic problems in the case of Bolivia and new health challenges in Catalonia and Spain.

About Clinic Foundation for Biomedical Research (Fundació Clínic per a la Recerca Biomédica)
Fundació Clínic per a la Recerca Biomèdica (FCRB) manages the administrative infrastructure supporting research at Hospital Clínic in Barcelona, the Biomedical Research Institute Agustí Pi i Sunyer (IDIBAPS) and CRESIB. Since 1989, the FCRB has been fostering health science-related research and training. In addition to providing administrative support to research, it participates in raising resources and fostering biomedical research. The Foundation also supports specialised training activities and sees to that ethical codes in the sector are complied with and that professional ethics are applied. CRESIB uses this Foundation to carry out its cooperation activities. FCRB has played an essential role in the creation and development of a Chagas platform in Bolivia, and others including the creation and development of CISM in Mozambique and the Fundaçao Manhiça, recently created to manage this centre. Also worth highlighting, is the role FCRB plays in the National Programme to bolster Mother and Child Healthcare Strategies, health research and training of specialists in Morocco.


For further information, go to www.dndi.org or www.cresib.cat

Media contacts

DNDi
Eva van Beek, Communications Manager
Mob: +41 (0)79 309 39 10 / T: +41 (0)22 906 92 30
evanbeek@dndi.org
www.dndi.org

CRESIB
Cristina de Carlos
Mob. +34 648725361 Tel.: +34 93 227 54 00 ext. 4113
cristina.decarlos@cresib.cat

Fundación Clínic per a la Recerca Biomédica
Marc de Semir
Tel.: +34 93 227 54 00
mdesemir@clinic.ub.es

Partnership Chagas disease

Read, watch, share

Loading...
Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo